Write a composition specification for buffered or unbuffered magnesium glycinate

Translate the label into a material definition

Trade descriptions are not a substitute for a bill of composition. In a sourcing discussion, “buffered” may refer to a formulation containing additional magnesium compounds, but the buyer needs the actual declaration rather than an assumed recipe. Ask whether magnesium oxide or another magnesium source is intentionally present and how it is described in technical and commercial documents.

“Unbuffered” is also not a complete analytical statement. It does not by itself state water content, residual reactants, permitted processing aids, assay basis or identity-test acceptance criteria. The formula in a chemical database identifies a compound; it does not certify that every similarly named commercial powder has that exact composition. [1]

Compare the materials using a common brief

Send the same brief to each candidate. If one quotation uses dry-basis assay and another uses an as-received value, normalize the comparison before discussing value per kilogram of elemental magnesium. Keep the commercial price comparison separate from the question of whether the ingredient fits the proposed label and product specification.

On smaller screens, scroll the table horizontally.

Make the selection in steps

For a powder product, that trial may focus on blend behavior and filling. For a beverage, it may focus on clarity, sediment, taste and stability. Equal elemental magnesium in two prototypes does not mean the prototypes contain the same total ingredient mass, so record both quantities when comparing performance.

• Define the intended composition and claims with your formulation and regulatory teams before selecting a trade description.
• Review the supplier’s signed specification and representative analytical package. Resolve discrepancies between its label, COA and technical sheet.
• Qualify identity and compositional tests that address the actual material. An elemental assay alone cannot settle the composition question.
• Run a controlled application trial, then retain the accepted specification, sample identity and reasons for the selection.

Avoid conclusions the evidence cannot support

Neither description establishes superior bioavailability or a clinical benefit. Those claims require evidence about the relevant ingredient and use, not an inference from a product name. Similarly, an unexplained high assay should trigger a composition review, not an automatic conclusion that a supplier has added a particular compound.

The practical endpoint is an approved material definition that purchasing, the laboratory and production can all use. Component specifications serve the finished-product manufacturer’s identity, composition and contamination-control needs; the exact application must determine what additional purchasing criteria are useful. [2]